Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, Gruget C, Olivier V, Picarel-Blanchot F, de Bodinat C. Stein DJ, et al. Among authors: olivier v. Eur Neuropsychopharmacol. 2017 May;27(5):526-537. doi: 10.1016/j.euroneuro.2017.02.007. Epub 2017 Mar 12. Eur Neuropsychopharmacol. 2017. PMID: 28298261 Free article. Clinical Trial.
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ, Khoo JP, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C, Bauer M, Bitter I, Mosolov SN, Olivier V, Matharan S, Picarel-Blanchot F, de Bodinat C. Stein DJ, et al. Among authors: olivier v. Eur Neuropsychopharmacol. 2018 Aug;28(8):970-979. doi: 10.1016/j.euroneuro.2018.05.006. Epub 2018 Jul 6. Eur Neuropsychopharmacol. 2018. PMID: 30135032 Clinical Trial.
Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
Arango C, Buitelaar JK, Fegert JM, Olivier V, Pénélaud PF, Marx U, Chimits D, Falissard B; study investigators. Arango C, et al. Among authors: olivier v. Lancet Psychiatry. 2022 Feb;9(2):113-124. doi: 10.1016/S2215-0366(21)00390-4. Epub 2021 Dec 14. Lancet Psychiatry. 2022. PMID: 34919834 Clinical Trial.
The safety of agomelatine in standard medical practice in depressed patients: A 26-week international multicentre cohort study.
Gorwood P, Benichou J, Moore N, Álvarez Martínez E, Mertens J, Aguglia E, Figueira ML, Falkai P, Olivier V, Wattez M, Picarel-Blanchot F, de Bodinat C. Gorwood P, et al. Among authors: olivier v. Hum Psychopharmacol. 2021 Jan;36(1):1-11. doi: 10.1002/hup.2759. Epub 2020 Sep 25. Hum Psychopharmacol. 2021. PMID: 32976677 Free PMC article.
87 results